156406-33-6 Usage
Description
9-Keto Fluprostenol is an analog of prostaglandin E2 (PGE2) that has been structurally modified to enhance its half-life and potency. Derived from the well-studied potent analog of PGF2α, Fluprostenol, which primarily acts through the FP receptor, 9-Keto Fluprostenol is produced through the oxidation at C-9 of fluprostenol. It is expected to have a strong affinity for EP receptors and function as a PGE2 agonist. However, there is a lack of published pharmacological studies on this compound to date.
Uses
Used in Pharmaceutical Industry:
9-Keto Fluprostenol is used as an impurity of Fluprostenol (F500753) for the development and analysis of FP prostaglandin receptor agonists. Its structural modifications and potential agonist activity for EP receptors make it a compound of interest in the pharmaceutical sector, particularly for research and development of new drugs targeting prostaglandin receptors.
Please note that the provided materials do not specify any other industries or application types for 9-Keto Fluprostenol. The information given is primarily focused on its role as an analog of prostaglandin E2 and its potential use in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 156406-33-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,4,0 and 6 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 156406-33:
(8*1)+(7*5)+(6*6)+(5*4)+(4*0)+(3*6)+(2*3)+(1*3)=126
126 % 10 = 6
So 156406-33-6 is a valid CAS Registry Number.
156406-33-6Relevant articles and documents
9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
-
Page/Page column 17-18, (2010/11/30)
9,11-Cycloendoperoxide derivatives of biologically active prostaglandin analogs, and particularly of the ocular hypotensive drugs Bimatoprost, Latanaprost, Unoprostone, Travoprost and prostaglandin H2 1-ethanolamide or of structurally closely related analogs, are pro-drugs which hydrolyze under physiological conditions to provide prostaglandin analogues that are capable of providing sustained ocular and other in vivo concentrations of the respective drugs. The compounds of the invention have the formula shown below where the variables have the meaning defined in the specification.
